Konstantinov Konstantin B, Cooney Charles L
Late Stage Process Development, Science, Genzyme- A Sanofi Company, 45 New York Ave., Framingham, MA, 01702.
J Pharm Sci. 2015 Mar;104(3):813-20. doi: 10.1002/jps.24268. Epub 2014 Nov 21.
There is a growing interest in realizing the benefits of continuous processing in biologics manufacturing, which is reflected by the significant number of industrial and academic researchers who are actively involved in the development of continuous bioprocessing systems. These efforts are further encouraged by guidance expressed in recent US FDA conference presentations. The advantages of continuous manufacturing include sustained operation with consistent product quality, reduced equipment size, high-volumetric productivity, streamlined process flow, low-process cycle times, and reduced capital and operating cost. This technology, however, poses challenges, which need to be addressed before routine implementation is considered. This paper, which is based on the available literature and input from a large number of reviewers, is intended to provide a consensus of the opportunities, technical needs, and strategic directions for continuous bioprocessing. The discussion is supported by several examples illustrating various architectures of continuous bioprocessing systems.
在生物制品制造中实现连续加工的益处正引发越来越多的关注,这体现在大量积极参与连续生物加工系统开发的工业界和学术界研究人员身上。美国食品药品监督管理局(FDA)近期会议报告中表达的指导意见进一步推动了这些努力。连续制造的优势包括以一致的产品质量持续运行、减小设备尺寸、提高体积生产率、简化工艺流程、缩短工艺周期时间以及降低资本和运营成本。然而,这项技术也带来了挑战,在考虑常规实施之前需要加以解决。本文基于现有文献以及众多审稿人的意见,旨在就连续生物加工的机遇、技术需求和战略方向达成共识。讨论辅以多个示例,展示了连续生物加工系统的各种架构。